Brucellosis. Brucellosis due to Brucella melitensis
Conditions
Interventions
Treatment - Drugs
Intervention 1: In case group : ciprofloxacin 500mg twice aday and doycycline 100mg twice a day for two months. Intervention 2: In control group Rifampicin 300mg BID & Doxycyclin 100mg BID for two mou
In case group : ciprofloxacin 500mg twice aday and doycycline 100mg twice a day for two months
In control group Rifampicin 300mg BID & Doxycyclin 100mg BID for two mounths
Sponsors
Arak University of Medical Sciences
Eligibility
Sex/Gender
All
Age
17 Years to 76 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria : patients with brucellosis in basis of clinical, epidemiological and serologic criteria, attended in the clinics of infectious disease in Arak university of medical sciences and age more than 17 years old. Excusion criteria : pregnancy; age less than 17 years; endocarditis - meningitis ; spondy lities, esophagitis ; consumption of oral contraceptives or phenytion; history of brucellosis (relapse), antimicrobial therapy for more than 7 days befor attending; intolerance for oral medication and no desire for patipicating.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical improvement. Timepoint: At the beginning of the study - second & third & and nine months serologic test in second & sixth& mounths. Method of measurement: Patients' history and physical exam and serologic results(clinical , wrigth , 2ME , serologic). | — |
Secondary
| Measure | Time frame |
|---|---|
| Failure of the treatment. Timepoint: Three mounth. Method of measurement: Clinical improvment and serology.;Drug side effects. Timepoint: During the treatment. Method of measurement: Clinical assessment.;Relapse. Timepoint: Sixth & ninth mounths from the begining of the study. Method of measurement: Clinical improvment and serology. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Farshideh Didgar
Arak University of Medical Sciences
Outcome results
None listed